Tag Archives: Career

RappAround Seeking Showroom Coordinator / Junior Account Executive and Fashion PR Intern In Los Angeles | Instant News

About RappAround Public Relations Consultation

RappAround Public Relations Consulting partners with elite brands to create and execute outstanding public relations and branding campaigns. Specializing in the fashion and lifestyle industry, RappAround is a full service boutique with full service capabilities. Based in Los Angeles, Melissa Rappaport and RappAround offer a one-stop shop for brands seeking deeper participation in the pop culture industry: media campaigns, celebrity seeding, influencer placement, hosting events, and most importantly, personal attention. From the La Cienega Boulevard office in West Hollywood, RappAround leverages every aspect of modern technology to place an immediate, global and creative footprint in the modern media stream.


image source

ANGLE PLC Announces Global Launch of the Clinical Services Laboratory | Instant News

  • Delivered a strategy to accelerate the commercialization of the Parsortix system and act as a demonstrator to support product deployment
  • UK and US clinical laboratories are now open and ready to provide analysis services and ongoing CTC discussions with pharmaceutical industry customers

GUILDFORD, SURREY / ACCESS / 30 March 2021 / ANGLE plc (AIM: AGL) (OTCQX: ANPCY), the world’s leading fluid biopsy company, is pleased to announce that they have completed fitout and staffing at clinical services laboratories in Guildford UK, and Plymouth Meeting PA, USA. The launch was ahead of schedule with US laboratories completing earlier than anticipated and UK laboratories opening at the anticipated timeframe. Together, these laboratories will enable ANGLE to accelerate the commercial deployment of Parsortix® systems by offering services to pharmaceutical and biotechnological customers for use in clinical trials of cancer drugs and, once the laboratory is accredited and tests validated, through the provision of Laboratory Developed Tests (LDTs) for patient care.

ANGLE samples to answer the liquid biopsy solution via a simple blood test allow longitudinal monitoring of the patient during drug trials (before, during and after drug intervention) which is not possible with tissue biopsy. This is a significant market opportunity for ANGLE. In one segment of this market, there are more than 2,000 PD-L1 / PD-1 intervention trials registered on clinicaltrials.gov, enrolling more than 300,000 patients, who would be potential targets for ANGLE’s pharmaceutical services business.

ANGLE is targeting future clinical studies for the application of the Parsortix system and has developed service capabilities in the United Kingdom and the United States to process samples on a commercial scale as part of global pharmaceutical trials. ANGLE has established dialogues with potential customers and collaborators on the application of CTC liquid biopsy analysis in cancer drug trials, with these conversations at an advanced stage.

Both UK and US laboratories will seek ISO15189 accreditation and US laboratories will also seek Clinical Laboratory Improvement Amendments (CLIA) accreditation, allowing them to market LDTs ​​for clinical use. Given the extensive clinical work that has been completed with the Ovarian Cancer Pelvic Mass Triage trial, it is anticipated that this will be ANGLE’s first LDT to be marketed.

ANGLE Founder and Chief Executive, Andrew Newland, comments: “The new clinical service laboratory is an important element in the Company’s commercial strategy and we are pleased to launch a global offering ahead of schedule. This will accelerate the commercialization of the Parsortix system and act as a demonstrator to support product implementation. As well as working with pharmaceutical company customers directly, we would like to work with contract research organizations as both a white label service and, when they wish to implement the test internally, by supplying the Parsortix system so they can immediately offer their own CTC services for cancer drug trials This will allow us to measure the commercial use of the Parsortix system in this large market. We are in follow-up discussions with potential customers and we look forward to renewing the market on the first contract in due time. “

For more information on ANGLE:


+44 (0) 1483 343434

Andrew Newland, Chief Executive

Ian Griffiths, Director of Finance

Andrew Holder, Head of Investor Relations

finnCap Ltd (NOMAD and Joint Brokerage)

Corporate Finance – Carl Holmes, Simon Hicks, Teddy Whiley

ECM – Alice Lane, Sunila de Silva

+44 (0) 20 7220 0500

WG Partners (Joint Brokers)

Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee

+44 (0) 203 705 9330

FTI Consultation

Simon Conway, Ciara Martin

Matthew Ventimiglia (USA)

+44 (0) 203 727 1000

+1 (212) 850 5624

Information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2015.

For Frequently Used Terms, please see the Company’s website at https://angleplc.com/investor-relations/glossary/

About ANGLE plc
CORNER is the world’s leading fluid biopsy company with sample-to-answer solutions. ANGLE’s patent-protected platform includes circulating tumor cell (CTC) harvesting technology and a downstream analysis system for highly multiplex and cost-effective protein and nucleic acid analysis.

The ANGLE cell separation technology is called Parsortix® system, and allows a liquid biopsy (simple blood test) to be used to provide the user with the desired cells in a format suitable for various types of downstream analysis. The system is based on a microfluidic device that captures cells based on their combination of size and compressibility. The system is epitope independent and can capture all types of CTC as well as cluster CTCs in viable (live) form. CTCs allow a complete picture of a cancer to be viewed as an intact cell. CTC allows analysis of DNA, RNA and protein and thus provides an analysis comparable to a tissue biopsy. Since CTC analysis is a noninvasive process, unlike a tissue biopsy, this analysis can be repeated as often as necessary. This is important because cancer develops and changes over time and there is a clear medical need for up-to-date information about its status. Additionally, live-harvested CTCs can be cultivated, which offers the potential for testing response to drugs outside the patient.

Parsortix technology is the subject of 26 patents granted in Europe, United States, China, Australia, Canada, India, Japan and Mexico with three broad patent groups being developed around the world.

The Parsortix system has the CE Mark in Europe for indicated use and, in the United States, a De Novo Filing has been made to the FDA for Parsortix® The PC1 system seeks FDA Classification Class II clearance for use with metastatic breast cancer patients. FDA clearance is seen as a global standard. ANGLE seeks to be the first FDA-approved system to harvest CTC for further analysis.

ANGLE has also completed two separate 200-subject clinical studies under a program designed to develop the ovarian cancer pelvic mass triage test, with results showing a best-in-class accuracy (AUC-ROC) of 95.1%. The pelvic mass triage trial has undergone further refinement and optimization and is currently in the process of a clinical verification study of 200 patients.

ANGLE’s technology for the evaluation of multiplex proteins and nucleic acids of all types is called HyCEADTM Ziplex® platform and is based on a patented flow through array technology. It provides low cost, highly multiplex, fast and sensitive target capture of a wide variety of sample types. The proprietary chemistry approach (the HyCEAD method) allows the capture and amplification of more than 100 biomarkers simultaneously in a single reaction. The HyCEAD Ziplex system is highly sensitive and ideal for measuring the expression of genes and other markers directly from the Parsortix harvest and used in the ovarian cancer pelvic mass triage test to achieve a best-in-class accuracy (AUC-ROC) of 95.1%.

ANGLE’s proprietary technologies can be combined to provide automated sample-to-answer results in centralized laboratories and use-site cartridge formats.

ANGLE has established formal collaborations with world-class cancer centers and major companies such as Abbott, Philips and QIAGEN, and works closely with leading CTC’s translational research customers. These Lead Opinion Leaders (KOLs) work to identify applications with medical utility (clear benefit to patients), and to secure clinical data demonstrating that usefulness in patient studies. Evidence on the benefits of the Parsortix system is growing rapidly from our own clinical studies on metastatic breast cancer and ovarian cancer and also from KOL with 41 peer-reviewed publications and many publicly available posters, available on our website.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as the Primary Information Provider in the UK. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.


Check out the source version on accesswire.com:


image source

‘Unprecedented’: Wall Street Ponders Goldman Block-Trade Spree | Instant News

Photographer: Michael Nagle / Bloomberg

As Wall Street speculates about the identity of the mysterious seller behind the massive $ 10.5 billion block trade carried out on Friday by Goldman Sachs Group Inc., investors are also pondering how unprecedented the sell-off is – and whether there’s more to come. will come.

The sale lit up chat rooms for traders from New York to Hong Kong and was part of an extraordinary streak that wiped $ 35 billion off the value of major stocks ranging from Chinese tech giants to US media conglomerates.

“I haven’t seen anything this big in my 25 years of career,” said Michel Keusch, portfolio manager at Bellevue Asset Management AG in Switzerland.

Goldman sold $ 6.6 billion in shares of Baidu Inc., Tencent Music Entertainment Group and Vipshop Holdings Ltd. before markets open in the US, according to an email to clients seen by Bloomberg News. The move was followed by the sale of a $ 3.9 billion stake in ViacomCBS Inc., Discovery Inc., Farfetch Ltd., iQiyi Inc. and GSX Techedu Inc., said the email.

Block trades – the sale of most shares at prices that are sometimes negotiated outside the market – are common, but the size of these trades and the few blocks that hit the market during normal trading hours are not.

“This is very unusual,” said Oliver Pursche, senior vice president at Wealthspire Advisor, which manages $ 12 billion in assets. “The question now is: Are they finished? Is this over already? Or come Monday and Tuesday, will the market be hit by another wave of trading blocks? “

Read More: Goldman Sold $ 10.5 Billion Shares on the Block-Trade Spree

The trade sparked price swings for each share engaged in high-volume transactions, rattled traders and sparked talk that the hedge fund or family office was in trouble and being forced to sell.

The situation is worrying “because we don’t have all the answers whether this is liquidating just one fund or more of a fund, or whether it was liquidating funds to initiate and the reasons behind it,” said Pursche.

“It might be difficult for a manager from a positioning point of view. Another wave of bloc trading could force investment managers to reassess their commitments to some stocks, “he said.

‘Never before’

Frederik Hildner, portfolio manager at Salm-Salm & Partner GmbH in Wallhausen, Germany, called the move “unprecedented”. He added, “The question is why is this block trading happening? Does one company know something no one else knows or are they forced to cut risks?


image source

The Ministry of Foreign Affairs wants career diplomats as envoys to India | Instant News

ISLAMABAD – The foreign ministry wants a career diplomat to be placed as High Commissioner for India as the two countries seek to normalize diplomatic relations, senior officials said yesterday.

A foreign ministry official told The Nation that the appointment of a non-career diplomat may not get the desired outcome for Islamabad.

This comes amid rumors that the Prime Minister’s Special Assistant for National Security Moeed Yusuf is being considered for a slot.

This speculation was immediately denied by Moeed Yusuf. “I know there are too many requests for news to be fact-checked before it is published today. But at least the story shouldn’t defy all logic. It is completely contrived and baseless, ”he tweeted, referring to a report.

A media report suggested that there was a high probability of Yusuf’s appointment as High Commissioner for India as the two countries had shown positive signs of reconciliation over the past few days.

Prior to joining the government, SAPM was Associate Vice President for Asia at the United States Institute of Peace in Washington, and previously a Fellow of the Frederick S Pardee Center for the study of the Longer-Range Future at Boston University’s Pardee School of Global Studies. He was appointed Special Assistant to the Prime Minister of the National Security and Strategic Policy Planning Division in December 2019.

Foreign Ministry officials said Prime Minister Imran Khan and Foreign Minister Shah Mehmood Qureshi could elect anyone for the position but the diplomatic corps would support a career diplomat for the job.

“There are so many choices. The foreign ministry will select a career diplomat. Hopefully it happens like that, “said an official.

In February 2019, Pakistan asked India to cut its staff in half at its embassy in Islamabad, just hours after New Delhi announced a similar decision. Those envoys – Moinul Haq and Ajay Bisaria – were also called upon to lower diplomatic ties.

The reciprocal move comes amid heightened tensions between rival nuclear-armed South Asian nations over the long-running Kashmir dispute.

While expulsion of diplomats is not unusual due to historically tense relations, the latest diplomatic row began when India expelled two Pakistani officials for “espionage,” prompting Pakistan to do the same in response.

Islamabad was quick to reject and condemn what it said was India’s baseless accusation of seeking a 50% reduction in staff strength at the Pakistan High Commission.

Bilateral tensions worsened in August 2019 when the government of Indian Prime Minister Narendra Modi unilaterally stripped India’s part of Kashmir from its decades-old constitutional semi-autonomous status.

New Delhi has also placed the Muslim-majority region under tight security and communications lockdown to prevent a violent reaction to the move, although some restrictions have been partially reduced.

Officials said Pakistani envoy to Canada Raza Bashir Tarar and ambassador to Turkey Muhammad Syrus Sajjad Qazi were among the candidates and that Moinul Haq could be withdrawn from China to continue on to New Delhi.

“So far no decision has been taken, but it will be announced soon. There are many senior diplomats so there is no problem, “said an official.

In recent weeks, Pakistan and India have made statements to resolve bilateral issues amicably.

There are reports that Foreign Minister Qureshi will meet Indian Foreign Minister S. Jaishankar on the sidelines of the ‘Heart of Asia’ conference in Tajikistan on March 30. Qureshi said he did not request a meeting but was open to any meeting.

The latest developments come after Pakistan Army Commander Qamar Javed Bajwa said in Islamabad that it is time to “bury the past and move forward.”

However, in a conference, General Bajwa added that the Kashmir issue “is clearly at the heart of this”. “It is important to understand that without settling the Kashmir dispute through peaceful means, the sub-continent rapprochement process will always be vulnerable to displacement due to politically motivated hostilities,” he said.

Earlier this month, Prime Minister Imran Khan also voiced peace against India and is fighting for greater trade ties with New Delhi.

Indian PM Narendra Modi welcomed PM Imran Khan this week to Pakistan Day and promised to work for peace.

Last month, the Director-General of Military Operations for Pakistan and India also agreed to keep the peace on the Line of Control, seen as the first step in a thaw in relations.


image source

Book review: Take a family healing journey in ‘Our Italian Summer’ | Art | Instant News

Our Italian Summer


Francesca Ferrari is a typical workaholic. She is a cruel single mother who prides herself on a spectacular career in advertising.

Building his business from scratch, he dedicated himself completely to his clients; whatever they ask, he delivers. Extremely devoted, Frannie sacrificed family time, personal relationships, and even potential business expansion in order to maintain her compulsive and obsessive need to take charge and direct every aspect of her thriving company. So begins the fascinating novel by Jennifer Probst: “Our Italian Summer.”

This novel begins with a typical day in Frannie’s career: overseeing a new client ad campaign. The boss interrogates staff, reviews strategy and dominates every aspect of the business, confidently ensuring their success and leaving no chance. Despite regretting that she missed her high school girls’ sporting events, this staunch woman refuses to let anything get in the way of her and the acquisition of other clients. But when she was faced with panic attacks during a planned meeting, Frannie began to focus less on her busy career and more on the two family members she had always left behind: her daughter and her mother.

Frannie’s daughter, Allegra, was a star student: not only was she outstanding with her studies, she was also a competent and successful athlete. However, while her mother pushed her to elite universities and career development internships, Allegra was constantly trying to make her own way. When she mentioned a desire to pursue a culinary career, Frannie immediately rejected the idea, seeing it as a job too under her brilliant daughter.


image source